An interventional study of 3D CEUS in Aneurysm Cerebral (Unruptured), sponsored by Resolve Stroke. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Resolve Stroke · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Intracranial Aneurysm with a site in France — 19 open to participants now, 26 under way, 1 of them phase 3. Intracranial Aneurysm · France.
Among the 66 studies in Intracranial Aneurysm with a site in France, this one is the 22nd largest by planned enrollment of the 23 interventional ones that give a count, is one of 6 that started in 2026, is one of 18 with no phase, reaches primary completion later than 5 of the 25 other live ones, and was the 66th registered.
419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
Browse Intracranial Aneurysm studies →19 of the 66 studies in Intracranial Aneurysm with a site in France are open now. Recruiting first, the newest first:
CHU de Reims · Sites in France
Ages 18+
Sim&Cure · Sites in France
Ages 18+
Phenox GmbH · Sites in France, Germany, Italy and 2 more countries
Hospices Civils de Lyon · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 104 across 208 interventional studies indexed under Intracranial Aneurysm.
Median enrollment 171 across the 23 interventional studies, 206 across the 43 observational. Of the 37 that completed or were terminated, 5 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 66 have an industry lead sponsor. The 10 most frequent:
Resolve Stroke is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Resolve Stroke has 1 study filed under Intracranial Aneurysm — fewer than ten, so there is no comparison to draw.
4 of the studies in Intracranial Aneurysm with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04192955Phase 3University of CalgaryEvaluating Oral Peri-operative Acetylsalicylic Acid in Subjects Undergoing Endovascular Coiling-only of Unruptured Brain Aneurysms | 2027-03 |
| NCT07864389Resolve StrokeMultimodal Approach Feasability Study for Untreated and Unruptured Intracranial Aneurysms | 2026-11 |
| NCT06940934Acandis GmbHPost-Market Product Surveillance of Intracranial ANeurysms Treated With Commercial ReGistered ACANDIS Devices in FrancE | 2026-12 |
| NCT06689410Nantes University HospitalMultimodal Biocollection Linked to the French Register of Intracranial Aneurysms | 2027-03-25 |
Add all 4 to your calendar (.ics) → With an account.
Among the 66 studies in Intracranial Aneurysm with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This feasibility study aims to evaluate the SYLVER system's ability to visualize intracranial aneurysms in accordance with 3D rotational angiography (3DRA) as the reference technique.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergo their standard-of-care diagnostic cerebral angiography, including 3D rotational angiography (3DRA), during a day hospitalization. During the same visit, a single research acquisition of 3D contrast-enhanced transcranial ultrasound is performed with the SYLVER imaging system (investigational, non-invasive, class IIa, not CE-marked) through the temporal acoustic window, after intravenous injection of an ultrasound contrast agent (SonoVue®). The research procedure lasts up to 30 minutes. Qualitative and quantitative hemodynamic parameters of the aneurysmal sac obtained with SYLVER are compared with 3DRA as the reference technique. Follow-up is limited to the day of the procedure.
Device: 3D CEUS
SYLVER is the investigational, non-invasive, class IIa ultrasound imaging system providing three-dimensional contrast-enhanced ultrasound (3D CEUS) imaging of the cerebral vasculature through the skull. Transcranial 3D CEUS acquisition is performed via the temporal acoustic window during the day-hospitalization for standard-of-care follow-up cerebral angiography, for a maximum of 30 minutes. Acquisitions are used to assess aneurysm presence, location and shape, intrasaccular flow organization (jet, recirculation, stagnation), filling completeness, and time-intensity curve and flow velocity parameters (time of arrival, time to peak, pulsatility index), which are compared with 3D rotational angiography.
Qualitative agreement between SYLVER 3D CEUS and 3D Rotational Angiography for aneurysmal sac hemodynamic analysis
Agreement between SYLVER 3D contrast-enhanced ultrasound and 3D rotational angiography (3DRA, reference technique) for qualitative parameters: aneurysm presence, location and shape; intrasaccular flow organization (jet, recirculation, stagnation); complete or partial sac filling. Agreement is expressed as observed percent agreement and, where relevant, kappa coefficient. Analysis is descriptive; no success threshold or statistical hypothesis is pre-specified.
Time frame: Day 1
Quantitative agreement between SYLVER 3D CEUS and 3D Rotational Angiography for aneurysmal sac hemodynamic parameters
Association and agreement between SYLVER 3D CEUS and 3DRA for quantitative hemodynamic parameters of the aneurysmal sac derived from the time-intensity curve (time of arrival, time to peak) and flow velocity (notably pulsatility index), analyzed in relation to intrasaccular flow organization. Association is assessed by Spearman correlation coefficient with 95% CI, and agreement by Bland-Altman limits of agreement. Analysis is descriptive.
Time frame: Day 1
Feasibility of the multimodal angiography and 3D Ultrasound approach
Number and percentage (with 95% CI) of participants with usable angiographic and ultrasound acquisitions, feasible co-registration of both modalities, and interpretable hemodynamic analysis of the aneurysmal sac.
Time frame: Day 1
Healthcare staff time with SYLVER
Time (minutes) spent by physicians, nursing assistants, radiographers and radiologists, measured with SYLVER.
Time frame: Day 1
Associated costs with SYLVER
Costs (euros) associated with the measured staff time, with SYLVER, to estimate the medico-economic impact of SYLVER use.
Time frame: Day 1
Incidence of Adverse Events, Serious Adverse Events and Device Deficiencies
Number and percentage of participants with adverse events (AEs) and serious adverse events (SAEs), and number of SYLVER device deficiencies, recorded in the eCRF.
Time frame: From inclusion to end of participation (Day 1)
Plan to share: No
Start is estimated for Oct 2026; primary completion for Nov 2026, 1 month later.
Of 47 industry-sponsored interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 49. This study's planned 1 month is below that.
Counting every sponsor, half of 106 studies reached it within 39 months; a quarter within 22 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Resolve Stroke